A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis
Status:
Completed
Trial end date:
2010-11-30
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy, safety and tolerability of once monthly
administration of subcutaneous Mircera for the maintenance of hemoglobin levels in patients
with chronic renal anemia not on dialysis.Patients will receive sc Mircera at a starting dose
of 100, 120, 200 or 360 micrograms every 4 weeks, calculated from the last weekly dose of ESA
previously administered. Subsequent doses will be adjusted to maintain hemoglobin levels
within the target range. The anticipated time on study treatment is 3-12 months, and the
target sample size is 100-500 individuals.